Arbutus Biopharma
D

ABUS

3.80000
USD
-0.03
(-0.65%)
مفتوح الان
آخر تحديث: · متأخرة 15 دقيقة
حجم التداول
9,300
الربح لكل سهم
-0
العائد الربحي
-
P/E
5
حجم السوق
582,448,447
أصول ذات صلة

العنوان: Arbutus Biopharma Corp

القطاع: الرعاية الصحية
الصناعة: Biotechnology
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

أسئلة شائعة حول سهم Arbutus Biopharma